JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
CAMBRIDGE, Mass., May 08, 2018 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Health Care Conference on Tuesday, May 15, 2018, at 8 a.m. PT (11:00 a.m. ET) in Las Vegas, Nevada.
A live webcast of the presentation will be available on the Investors & Media section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Contacts
Media:
Cristi Barnett
(617) 401-0113
[email protected]
Investors:
Mark Mullikin
(617) 401-9083
[email protected]
